Business Description
Maxygen, Inc.
ISIN : US5777761074
Description
Maxygen, Inc., is incorporated in Delaware. It is a biotechnology company. It discovers and develops improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. The Company's MAXY-G34 product candidate has been designed to be an improved next-generation pegylated, G-CSF for the treatment of chemotherapy-induced neutropenia. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The Company completed a Phase IIa clinical trial for its MAXY-G34 product candidate for the treatment of chemotherapy-induced neutropenia in breast cancer patients in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia with no serious adverse events, drug-related grade 3 or 4 adverse events or immunogenicity reported in any patient receiving MAXY-G34. Adverse events were consistent with known side effects of G-CSF molecules. The Company is subject to regulation by the FDA and comparable regulatory agencies in foreign countries with respect to any development and commercialization of its MAXY-G34 product candidate or any other products it may acquire in the future.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Interest Coverage | 123.07 |
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | 86.93 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 3.13 | |||||
| PE Ratio without NRI | 3.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Maxygen, Inc. Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 23.916 | ||
| EPS (TTM) (€) | 0.6 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 0 - 1.88 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Maxygen, Inc. Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Maxygen, Inc. Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Maxygen, Inc. Frequently Asked Questions
What is Maxygen, Inc.(FRA:MYN)'s stock price today?
The current price of FRA:MYN is €1.88. The 52 week high of FRA:MYN is €1.88 and 52 week low is €0.00.
When is next earnings date of Maxygen, Inc.(FRA:MYN)?
The next earnings date of Maxygen, Inc.(FRA:MYN) is .
Does Maxygen, Inc.(FRA:MYN) pay dividends? If so, how much?
Maxygen, Inc.(FRA:MYN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers